TWI546304B - Protein tyrosine kinase inhibitors and their use - Google Patents

Protein tyrosine kinase inhibitors and their use Download PDF

Info

Publication number
TWI546304B
TWI546304B TW103126236A TW103126236A TWI546304B TW I546304 B TWI546304 B TW I546304B TW 103126236 A TW103126236 A TW 103126236A TW 103126236 A TW103126236 A TW 103126236A TW I546304 B TWI546304 B TW I546304B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
amino
methyl
hydrogen
Prior art date
Application number
TW103126236A
Other languages
English (en)
Chinese (zh)
Other versions
TW201504239A (zh
Inventor
Yong Wang
li-wen Zhao
hong-yan Chen
de-zhong Wang
Yang Liu
Sheng Bi
Yi-Ping Gao
Di Zhang
Cang Zhang
Original Assignee
Nanjing Sanhome Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Sanhome Pharmaceutical Co Ltd filed Critical Nanjing Sanhome Pharmaceutical Co Ltd
Publication of TW201504239A publication Critical patent/TW201504239A/zh
Application granted granted Critical
Publication of TWI546304B publication Critical patent/TWI546304B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
TW103126236A 2013-07-31 2014-07-31 Protein tyrosine kinase inhibitors and their use TWI546304B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310329248.8A CN104341416B (zh) 2013-07-31 2013-07-31 蛋白酪氨酸激酶抑制剂及其应用

Publications (2)

Publication Number Publication Date
TW201504239A TW201504239A (zh) 2015-02-01
TWI546304B true TWI546304B (zh) 2016-08-21

Family

ID=52431006

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103126236A TWI546304B (zh) 2013-07-31 2014-07-31 Protein tyrosine kinase inhibitors and their use

Country Status (3)

Country Link
CN (1) CN104341416B (fr)
TW (1) TWI546304B (fr)
WO (1) WO2015014283A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749278B (zh) * 2016-12-29 2019-03-26 天津国际生物医药联合研究院 三氮唑类化合物的制备及其应用
WO2019043635A1 (fr) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. Composés inhibiteurs de l'activité de d-amino acide oxydase
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 ***并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008008152A (es) * 2005-12-23 2008-09-12 Ariad Pharma Inc Compuestos heterociclicos biciclicos.
WO2012139027A1 (fr) * 2011-04-07 2012-10-11 Ariad Pharmaceuticals, Inc. Procédés et compositions pour le traitement de maladies neurodégénératives
BR112013024169A2 (pt) * 2011-04-07 2016-12-06 Ariad Pharma Inc método para o tratamento e prevenção da doença de parkinson
RU2477723C2 (ru) * 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CN103421005A (zh) * 2012-05-16 2013-12-04 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
CN103848829B (zh) * 2012-11-28 2017-04-12 南京圣和药业股份有限公司 杂芳基炔烃化合物及其应用

Also Published As

Publication number Publication date
CN104341416B (zh) 2017-03-29
CN104341416A (zh) 2015-02-11
WO2015014283A1 (fr) 2015-02-05
TW201504239A (zh) 2015-02-01

Similar Documents

Publication Publication Date Title
JP6918898B2 (ja) 置換逆ピリミジンＢｍｉ−１阻害剤
CN109369671B (zh) 作为Raf激酶和/或Raf激酶二聚体抑制剂的稠合三环脲类化合物
EP2850082B1 (fr) 1-(3,3-diméthylbutyl)-3-(2-fluoro-4-methyl-5-(7-méthyl-2-(méthylamino)pyrido(2,3-d)pyrimidin-6-yl)phényl)urea en tant qu'inhibiteurs de la Raf pour le traitement de cancer
CN102625807B (zh) 4-取代的吡啶-3-基-甲酰胺化合物和使用方法
KR20110079887A (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
TWI523856B (zh) BCR-ABL kinase inhibitor and its application
JP7109919B2 (ja) Ｕｓｐ７阻害剤化合物及び使用方法
WO2014082578A1 (fr) Composé de type hétéroarylalcyne et ses applications
TWI822868B (zh) Ｆｇｆｒ４抑制劑、包含其的藥物組合物及其用途
TW200916458A (en) Heterocyclic compounds and methods of use thereof
JP2014533661A (ja) 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤
ES2709003T3 (es) Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico
WO2021244609A1 (fr) Composé ayant une structure macrocyclique et son utilisation
WO2019080723A1 (fr) Dérivé de pyridone polysubstitué, son procédé de préparation et son utilisation médicale
TWI546304B (zh) Protein tyrosine kinase inhibitors and their use
WO2018214866A1 (fr) Dérivé d'azaaryle, son procédé de préparation et son application pour une utilisation en pharmacie
WO2020221209A1 (fr) Inhibiteur de cd73, son procédé de préparation et son utilisation
TW202028195A (zh) 作為TGF-βR1抑制劑的化合物及其應用
CN110305125A (zh) 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
BRPI0717873A2 (pt) Derivado de 3-amino-pirazol-4-carboxamida úteis como inibidores de proteína quinases
EP4289427A1 (fr) Dihydro[1,8]naphthyridin-7-one et pyrido[3,2-b][1,4]oxazin-3-one pour une utilisation dans le traitement du cancer, et des métastases en particulier.
WO2023078267A1 (fr) Composé macrocyclique contenant un groupe amino utilisé en tant que modulateur de protéine kinase
WO2023030335A1 (fr) Composé utilisé en tant qu'inhibiteur du domaine de pseudokinase tyk2/jak1, et procédés de synthèse et d'utilisation
WO2023099072A1 (fr) Composés
WO2023045816A1 (fr) Composé benzocycloheptane utilisé comme inhibiteur d'axl

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees